New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:09 EDTEBSEmergent BioSolutions sees FY13 revenue $311M-$313M, consensus $307.84M.
The company also anticipates FY13 GAAP net income of $30M-$32M. Excluding approximately $7M of transaction-related and restructuring costs incurred during the year, the company is providing a forecast for 2013 non-GAAP adjusted net income of $35M-$37M.
News For EBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 10, 2014
07:29 EDTEBSEmergent BioSolutions seeks expanded BioThrax label
Emergent BioSolutions announced that it has submitted a supplemental Biologics License Application to the FDA seeking to expand the label of BioThrax to include a post-exposure prophylaxis indication. BioThrax, the only FDA-licensed vaccine to prevent anthrax disease, is currently licensed for a pre-exposure prophylaxis indication only. The company made a Request for Priority Review Designation to potentially reduce the anticipated approval of this application to six months. The sBLA proposes to expand the BioThrax indication to include a post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure when combined with the recommended course of antimicrobials in persons 18 through 65 years of age. The vaccination schedule consists of three doses of BioThrax administered at 0, 2, and 4 weeks post-exposure.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use